Literature DB >> 26234902

Rheb signaling and tumorigenesis: mTORC1 and new horizons.

Marisol E Armijo1, Tania Campos1, Francisco Fuentes-Villalobos1, Mario E Palma1, Roxana Pincheira1, Ariel F Castro1.   

Abstract

Rheb is a conserved small GTPase that belongs to the Ras superfamily, and is mainly involved in activation of cell growth through stimulation of mTORC1 activity. Because deregulation of the Rheb/mTORC1 signaling is associated with proliferative disorders and cancer, inhibition of mTORC1 has been therapeutically approached. Although this therapy has proven antitumor activity, its efficacy is not as expected. Here, we will review the main work on the identification of the role of Rheb in cell growth, and on the relevance of Rheb in proliferative disorders, including cancer. We will also review the Rheb functions that could explain tumor resistance to therapies with mTORC1 inhibitors, and will mainly focus our discussion on mTORC1-independent Rheb functions that could also be implicated in cancer cell survival and tumorigenesis. The current progress on the understanding of the noncanonical Rheb functions prompts future studies to establish their relevance in cancer and in the context of current cancer therapies.
© 2015 UICC.

Entities:  

Keywords:  Rheb; mTORC1; mTORC1-independent Rheb functions; rapamycin resistance

Mesh:

Substances:

Year:  2015        PMID: 26234902     DOI: 10.1002/ijc.29707

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  8 in total

Review 1.  Gankyrin as a potential therapeutic target for cancer.

Authors:  Chongchong Wang; Li Cheng
Journal:  Invest New Drugs       Date:  2017-05-19       Impact factor: 3.850

2.  TSC-insensitive Rheb mutations induce oncogenic transformation through a combination of constitutively active mTORC1 signalling and proteome remodelling.

Authors:  Jianling Xie; Stuart P De Poi; Sean J Humphrey; Leanne K Hein; John B Bruning; Wenru Pan; Luke A Selth; Timothy J Sargeant; Christopher G Proud
Journal:  Cell Mol Life Sci       Date:  2021-04-08       Impact factor: 9.261

3.  Blocking the Farnesyl Pocket of PDEδ Reduces Rheb-Dependent mTORC1 Activation and Survival of Tsc2-Null Cells.

Authors:  Marisol Estrella Armijo; Emilia Escalona; Daniela Peña; Alejandro Farias; Violeta Morin; Matthias Baumann; Bert Matthias Klebl; Roxana Pincheira; Ariel Fernando Castro
Journal:  Front Pharmacol       Date:  2022-06-23       Impact factor: 5.988

Review 4.  Chemical modulation of autophagy as an adjunct to chemotherapy in childhood and adolescent brain tumors.

Authors:  Juliette Servante; Jasper Estranero; Lisethe Meijer; Rob Layfield; Richard Grundy
Journal:  Oncotarget       Date:  2018-10-16

Review 5.  Drugging the Small GTPase Pathways in Cancer Treatment: Promises and Challenges.

Authors:  Néstor Prieto-Dominguez; Christopher Parnell; Yong Teng
Journal:  Cells       Date:  2019-03-16       Impact factor: 6.600

6.  Active receptor tyrosine kinases, but not Brachyury, are sufficient to trigger chordoma in zebrafish.

Authors:  Gianluca D'Agati; Elena María Cabello; Karl Frontzek; Elisabeth J Rushing; Robin Klemm; Mark D Robinson; Richard M White; Christian Mosimann; Alexa Burger
Journal:  Dis Model Mech       Date:  2019-07-16       Impact factor: 5.758

7.  Extensive molecular tinkering in the evolution of the membrane attachment mode of the Rheb GTPase.

Authors:  Kristína Záhonová; Romana Petrželková; Matus Valach; Euki Yazaki; Denis V Tikhonenkov; Anzhelika Butenko; Jan Janouškovec; Štěpánka Hrdá; Vladimír Klimeš; Gertraud Burger; Yuji Inagaki; Patrick J Keeling; Vladimír Hampl; Pavel Flegontov; Vyacheslav Yurchenko; Marek Eliáš
Journal:  Sci Rep       Date:  2018-03-27       Impact factor: 4.379

8.  circRNA MYLK Accelerates Cervical Cancer via Up-Regulation of RHEB and Activation of mTOR Signaling.

Authors:  Rui Chen; Luning Mao; Rui Shi; Wenjing Wang; Jingxin Cheng
Journal:  Cancer Manag Res       Date:  2020-05-19       Impact factor: 3.989

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.